Skip to content
Menu

Opus Genetics, Inc. IRD

Full chart Compare
Set alert

Price alert · IRD

All alert types
4.08 USD +0.16 (+4.08%)

Regular-session close

4.02 -0.06 -1.47%

After hours · Nov 19, 7:39 PM ET

3.93 Day range 4.12
1.86 52-week range 7.07
YTD
+102.99%
1 year
+119.35%

5D +0.07 (+1.76%)

3.803.9044.10FriMonTueWedThu4.05
Market cap
394.35M
Revenue (ttm)
8.38M
EPS (ttm)
-1.48
Shares out
31.57M
Forward P/E
-1.20
YTD return
+102.99%
1-year return
+119.35%
50-day average
1.13
Volume
598.16K
Avg volume
2.57M
Open
3.96
Previous close
3.92
Day's range
3.93 – 4.12
52-week range
1.86 – 7.07
Analysts
Strong Buy
Price target
10.50 (+157.4%)

Key statistics

200-day average
1.52
Enterprise value
-5.75M
Price / sales
3.88
Price / book
0.79
Revenue growth
-67.60%
Free cash flow
-8.28M
Total cash
36.63M
Return on equity
-64.30%
Short % of float
2.91%

Fundamental scorecard

5 of 25 checks passed on IRD’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IRD Revenue — quarterly 1.14M
IRD Net income — quarterly -46.49M
IRD EPS — quarterly -0.46

Earnings

IRD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.30-0.29+0.01+3.33%

Upgrades / downgrades

IRD analyst upgrades and downgrades
DateFirmActionFromTo
Dec 12, 2024HC Wainwright & Co.reitBuyBuy
Oct 23, 2024Canaccord GenuitymainBuyBuy
Aug 15, 2024HC Wainwright & Co.mainBuyBuy
Aug 14, 2024Canaccord GenuitymainBuyBuy
May 13, 2024Canaccord GenuitymainBuyBuy
May 13, 2024HC Wainwright & Co.reitBuyBuy

About Opus Genetics, Inc.

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
opusgtx.com

News

Your note

Sign in to keep a note on IRD — it syncs with the Stock Master app.

Institution ownership

IRD institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc3.14%992,2001.02MSep 29, 2024
Geode Capital Management, LLC0.86%272,281280.45KSep 29, 2024
Bridgeway Capital Management, Inc.0.53%165,751170.72KSep 29, 2024
Richmond Brothers, Inc.0.49%155,620160.29KSep 29, 2024
Blackrock Inc.0.35%109,323112.60KSep 29, 2024
Knoll Capital Management, LLC0.32%100,000103.00KSep 29, 2024

Fund ownership

IRD fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.14%675,815696.09KSep 29, 2024
Vanguard Extended Market Index Fund0.92%288,947297.62KSep 29, 2024
Fidelity Extended Market Index Fund0.45%142,910147.20KOct 30, 2024
Bridgeway Fds Inc-Omni Small Cap Value Fund0.25%80,40082.81KSep 29, 2024
iShares Micro Cap ETF0.18%57,64959.38KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Fund0.14%44,03645.36KSep 29, 2024